Daniel Jense

Daniel Janse is a Director at Northpond Ventures on the firm’s biotechnologies team. Daniel is also a Board Director at Aro Biotherapeutics and Triumvira Immunologics. Previously, Daniel was the Chief Operating Officer and Chief Business Officer at Arbor Biotechnologies, where he led scientific and general operations, business development, program and alliance management, and corporate development and strategy. Prior to Arbor, Daniel served in leadership positions in the U.S. and Europe at Juno Therapeutics, Johnson & Johnson Innovation Center, Inventages Venture Capital, and McKinsey & Company. Additionally, he was a Presidential Postdoctoral Fellow at Novartis Institutes for Biomedical Research in Austria. Daniel holds a Ph.D. from Harvard University, where he trained in the laboratory of Dr. George Church in the Department of Genetics. He earned a B.S. and B.A. with honors in biochemistry and economics from Brown University where he was an Oettinger National Scholar.